Correction to “Targeted Delivery of AR-V7 siRNA with Bivalent PSMA Aptamers Effectively Suppresses the Growth of Enzalutamide-Resistant Prostate Cancer”
- 13 August 2025
- journal article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (9) , 5710-5711
Abstract
No abstract availableFunding Information
- National Institute of Biomedical Imaging and Bioengineering (R21EB026564)
- U.S. Department of War (W81XWH-15-1-0333)
- U.S. Department of Health and Human Services (R43IP001233)
- National Institute of General Medical Sciences (R43GM151884)